Cargando…

Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea

OBJECTIVES: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). METHODS: Ful...

Descripción completa

Detalles Bibliográficos
Autores principales: Milojević, Ana, Zdravković, Marija, Brajković, Milica, Memon, Lidija, Gardijan, Vera, Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Mihajlović, Marija, Ivanišević, Jasmina, Bogavac-Stanojević, Nataša, Radosavljević, Vojislav, Spasojević-Kalimanovska, Vesna, Ninić, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274940/
https://www.ncbi.nlm.nih.gov/pubmed/35292607
http://dx.doi.org/10.1159/000524087
_version_ 1784745392884154368
author Milojević, Ana
Zdravković, Marija
Brajković, Milica
Memon, Lidija
Gardijan, Vera
Vekić, Jelena
Zeljković, Aleksandra
Stefanović, Aleksandra
Mihajlović, Marija
Ivanišević, Jasmina
Bogavac-Stanojević, Nataša
Radosavljević, Vojislav
Spasojević-Kalimanovska, Vesna
Ninić, Ana
author_facet Milojević, Ana
Zdravković, Marija
Brajković, Milica
Memon, Lidija
Gardijan, Vera
Vekić, Jelena
Zeljković, Aleksandra
Stefanović, Aleksandra
Mihajlović, Marija
Ivanišević, Jasmina
Bogavac-Stanojević, Nataša
Radosavljević, Vojislav
Spasojević-Kalimanovska, Vesna
Ninić, Ana
author_sort Milojević, Ana
collection PubMed
description OBJECTIVES: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). METHODS: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. RESULTS: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m<sup>2</sup>) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m<sup>2</sup> when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). CONCLUSION: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9.
format Online
Article
Text
id pubmed-9274940
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-92749402022-08-16 Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea Milojević, Ana Zdravković, Marija Brajković, Milica Memon, Lidija Gardijan, Vera Vekić, Jelena Zeljković, Aleksandra Stefanović, Aleksandra Mihajlović, Marija Ivanišević, Jasmina Bogavac-Stanojević, Nataša Radosavljević, Vojislav Spasojević-Kalimanovska, Vesna Ninić, Ana Med Princ Pract Original Paper OBJECTIVES: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). METHODS: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. RESULTS: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m<sup>2</sup>) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m<sup>2</sup> when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). CONCLUSION: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9. S. Karger AG 2022-03-15 /pmc/articles/PMC9274940/ /pubmed/35292607 http://dx.doi.org/10.1159/000524087 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
spellingShingle Original Paper
Milojević, Ana
Zdravković, Marija
Brajković, Milica
Memon, Lidija
Gardijan, Vera
Vekić, Jelena
Zeljković, Aleksandra
Stefanović, Aleksandra
Mihajlović, Marija
Ivanišević, Jasmina
Bogavac-Stanojević, Nataša
Radosavljević, Vojislav
Spasojević-Kalimanovska, Vesna
Ninić, Ana
Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
title Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
title_full Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
title_fullStr Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
title_full_unstemmed Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
title_short Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea
title_sort effects of apnea, obesity, and statin therapy on proprotein convertase subtilisin/kexin 9 levels in patients with obstructive sleep apnea
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274940/
https://www.ncbi.nlm.nih.gov/pubmed/35292607
http://dx.doi.org/10.1159/000524087
work_keys_str_mv AT milojevicana effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT zdravkovicmarija effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT brajkovicmilica effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT memonlidija effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT gardijanvera effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT vekicjelena effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT zeljkovicaleksandra effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT stefanovicaleksandra effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT mihajlovicmarija effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT ivanisevicjasmina effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT bogavacstanojevicnatasa effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT radosavljevicvojislav effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT spasojevickalimanovskavesna effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea
AT ninicana effectsofapneaobesityandstatintherapyonproproteinconvertasesubtilisinkexin9levelsinpatientswithobstructivesleepapnea